



***Giovedì 20 Febbraio, ore 15:00***


Aula Magna

Viale Regina Elena 295

**Dr. Massimo Gadina**



Translational Immunology Section, Office of Science and  
Technology, National Institute of Arthritis Musculoskeletal and  
Skin Diseases, National Institutes of Health, Bethesda, MD, United  
States



***Targeting signaling in immune-mediated  
diseases: The coming of age of JAK inhibitors***

*Drugs targeting the Janus kinases (JAKs) have only recently entered the clinical armamentarium. First generation pan-JAK inhibitors are now used worldwide for the treatment of autoimmune diseases as well as malignancies. More selective, second-generation JAK inhibitors are now being developed and several have already reached the late stages in clinical trials for a variety of immune-mediated pathologies. I will review the most recent findings related to JAK inhibitors' mechanism of action and some of the newest diseases for which inhibition of the JAK-STAT pathway is proving to be a successful therapeutic approach or actively investigated.*



**ISTITUTO PASTEUR ITALIA**  
FONDAZIONE CENCI BOLOGNETTI

---

**LA RICERCA IN PERSONA**